AU2010233791B2 - Therapeutic agents for the treatment of diseases associated with undesired cell proliferation - Google Patents

Therapeutic agents for the treatment of diseases associated with undesired cell proliferation Download PDF

Info

Publication number
AU2010233791B2
AU2010233791B2 AU2010233791A AU2010233791A AU2010233791B2 AU 2010233791 B2 AU2010233791 B2 AU 2010233791B2 AU 2010233791 A AU2010233791 A AU 2010233791A AU 2010233791 A AU2010233791 A AU 2010233791A AU 2010233791 B2 AU2010233791 B2 AU 2010233791B2
Authority
AU
Australia
Prior art keywords
lif
cancer
cell
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010233791A
Other languages
English (en)
Other versions
AU2010233791A1 (en
Inventor
Jose Baselga Torres
Silvia Penuelas Prieto
Joan Seoane Suarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron Ir Huvh
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron Ir Huvh, Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron Ir Huvh
Publication of AU2010233791A1 publication Critical patent/AU2010233791A1/en
Application granted granted Critical
Publication of AU2010233791B2 publication Critical patent/AU2010233791B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
AU2010233791A 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation Ceased AU2010233791B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200900928 2009-04-03
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Publications (2)

Publication Number Publication Date
AU2010233791A1 AU2010233791A1 (en) 2011-11-03
AU2010233791B2 true AU2010233791B2 (en) 2016-01-21

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010233791A Ceased AU2010233791B2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Country Status (24)

Country Link
US (4) US10100112B2 (cg-RX-API-DMAC7.html)
EP (2) EP2414394A2 (cg-RX-API-DMAC7.html)
JP (5) JP6207836B2 (cg-RX-API-DMAC7.html)
KR (6) KR102373754B1 (cg-RX-API-DMAC7.html)
CN (2) CN107964043A (cg-RX-API-DMAC7.html)
AU (1) AU2010233791B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015369A2 (cg-RX-API-DMAC7.html)
CA (1) CA2757680C (cg-RX-API-DMAC7.html)
CY (1) CY1124148T1 (cg-RX-API-DMAC7.html)
DK (1) DK3045474T3 (cg-RX-API-DMAC7.html)
EA (1) EA201101450A1 (cg-RX-API-DMAC7.html)
ES (2) ES2363358B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20210352T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054196T2 (cg-RX-API-DMAC7.html)
IL (1) IL215467A (cg-RX-API-DMAC7.html)
LT (1) LT3045474T (cg-RX-API-DMAC7.html)
MX (1) MX336903B (cg-RX-API-DMAC7.html)
PL (1) PL3045474T3 (cg-RX-API-DMAC7.html)
PT (1) PT3045474T (cg-RX-API-DMAC7.html)
SG (2) SG10202010568RA (cg-RX-API-DMAC7.html)
SI (1) SI3045474T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010115868A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107215B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010394A2 (en) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
IN2014MU00815A (cg-RX-API-DMAC7.html) * 2014-03-11 2015-09-25 Godavari Biorefineries Ltd
CN112494646A (zh) * 2014-06-30 2021-03-16 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
JP2017527582A (ja) * 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
AU2016235298B2 (en) 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
EP3807315A2 (en) * 2018-06-18 2021-04-21 MedImmune Limited Methods for improving response to anti-lif antibody treatment in individuals with cancer
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
JP7501876B2 (ja) * 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
AU632993B2 (en) 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
EP2321433A2 (en) * 2008-08-29 2011-05-18 F. Hoffmann-La Roche AG Diagnostics and treatments for vegf-independent tumors
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELLOKUMPU-LEHTINEN, P., et al., "Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways," International Journal of Cancer, 1996, Vol. 66, No. 4, pages 515-519 *

Also Published As

Publication number Publication date
KR20220035978A (ko) 2022-03-22
IL215467A0 (en) 2011-12-29
JP2019006784A (ja) 2019-01-17
SG10202010568RA (en) 2020-11-27
JP2020090522A (ja) 2020-06-11
KR102373754B1 (ko) 2022-03-15
KR20170121319A (ko) 2017-11-01
JP7197665B2 (ja) 2022-12-27
EP2414394A2 (en) 2012-02-08
CA2757680C (en) 2021-11-02
BRPI1015369A2 (pt) 2021-06-29
EP3045474A3 (en) 2016-09-28
CN102574918A (zh) 2012-07-11
WO2010115868A2 (en) 2010-10-14
KR20200078668A (ko) 2020-07-01
MX336903B (es) 2016-02-04
JP2022031742A (ja) 2022-02-22
US20120114671A1 (en) 2012-05-10
WO2010115868A3 (en) 2011-02-03
SI3045474T1 (sl) 2021-07-30
CY1124148T1 (el) 2022-05-27
US20200385455A1 (en) 2020-12-10
JP2012522756A (ja) 2012-09-27
US11999782B2 (en) 2024-06-04
EP3045474A2 (en) 2016-07-20
JP2016040255A (ja) 2016-03-24
ES2864639T3 (es) 2021-10-14
AU2010233791A1 (en) 2011-11-03
ES2363358B1 (es) 2012-06-21
LT3045474T (lt) 2021-05-10
US20190211095A1 (en) 2019-07-11
PT3045474T (pt) 2021-03-22
CA2757680A1 (en) 2010-10-14
KR20120100703A (ko) 2012-09-12
ZA201107215B (en) 2012-12-27
KR20190093691A (ko) 2019-08-09
JP6207836B2 (ja) 2017-10-04
MX2011010425A (es) 2012-03-06
SG175032A1 (en) 2011-11-28
SMT202100153T1 (it) 2021-05-07
EA201101450A1 (ru) 2012-04-30
HUE054196T2 (hu) 2021-08-30
IL215467A (en) 2016-06-30
US10100112B2 (en) 2018-10-16
US20240400667A1 (en) 2024-12-05
KR20180079470A (ko) 2018-07-10
PL3045474T3 (pl) 2021-08-09
ES2363358A1 (es) 2011-08-01
CN107964043A (zh) 2018-04-27
DK3045474T3 (da) 2021-03-22
HRP20210352T1 (hr) 2021-05-28
EP3045474B1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
US20240400667A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
JP7410211B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
HK1229338A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338B (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EA040048B1 (ru) Фармацевтическая композиция и способ лечения глиомы, характеризущейся наличием высоких уровней lif
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired